Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.77 |
| ▸ | PPARG | P37231 | 5/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683371 | 0.99 | AGTR2 (0.78) | AGTR2PPARGAGTR1 | |
| SCHEMBL2927273 | 0.99 | AGTR2 (0.77) | AGTR2PPARGAGTR1 | |
| SCHEMBL5548451 | 0.92 | AGTR2 (0.67) | AGTR2PPARGAGTR1 | |
| SCHEMBL15702902 | 0.90 | AGTR2 (0.83) | AGTR2PPARGAGTR1 | |
| SCHEMBL2132264 | 0.89 | AGTR2 (0.63) | AGTR2AGTR1 | |
| SCHEMBL683639 | 0.89 | AGTR2 (0.65) | AGTR2PPARGAGTR1 | |
| SCHEMBL683650 | 0.88 | AGTR2 (0.87) | AGTR2PPARGAGTR1 | |
| SCHEMBL682531 | 0.88 | AGTR2 (0.84) | AGTR2PPARGAGTR1 | |
| Azilsartan Medoxomil SCHEMBL30770646 | 0.88 | AGTR2 (0.99) | AGTR2PPARGAGTR1 | |
| Azilsartan Medoxomil SCHEMBL967313 | 0.88 | AGTR2 (0.99) | AGTR2PPARGAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172401-A1 | BENZIMIDAZOLE DERIVATIVE AND USE AS ANGIOTENSIN II ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | claimed |
| EP-1863801-B1 | BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2010-09-29 | — | — | EP | claimed |
| US-20090054502-A1 | Benzimidazole Derivative and Use as Angiotensin II Antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-02-26 | — | — | US | claimed |
| US-20120172401-A1 | BENZIMIDAZOLE DERIVATIVE AND USE AS ANGIOTENSIN II ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | disclosed |
| US-20090054502-A1 | Benzimidazole Derivative and Use as Angiotensin II Antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172401-A1 | BENZIMIDAZOLE DERIVATIVE AND USE AS ANGIOTENSIN II ANTAGONIST | AGTR2, AGTR1, ACE | AGTR2 1/4885PPARG 1405/4885AGTR1 2/4885 |
| US-20090054502-A1 | Benzimidazole Derivative and Use as Angiotensin II Antagonist | AGTR2, AGTR1, ACE | AGTR2 1/4885PPARG 1405/4885AGTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.